Dr. Kirk Taylor has over 26 years of experience in global drug development programs, from Phase 1 through post-approval studies, across multiple therapeutic areas including neurology and rare diseases. He is joining BrainStorm from EMD Serono, where, as Senior Vice President, North American Medical Affairs, he led the medical team’s efforts across four therapeutic areas and the launch of three new treatments. Prior to EMD Serono, Kirk served as Senior Vice President, Medical Affairs Strategy and Operations at Verastem Oncology and CMO and Chief of Strategy and Late Phase Development at Finch Therapeutics Group, where he defined a plan for filing and commercializing the company’s internal assets. Earlier in his career, Kirk held high-profile roles in medical functions at large pharmaceutical companies such as Biogen, Pfizer and Sanofi-Genzyme, where he drove Late Phase development strategy for many successful CNS products.

Dr. Taylor holds an M.D. from State University of New York Downstate and a B.A. from Harvard University. He completed a neurology residency at the Albert Einstein College of Medicine and a postdoctoral fellowship in pain management at the University of California, San Francisco. He taught pain management to neurology residents while on faculty at Yale VA Hospital for two years.  He has completed executive leadership training from Harvard, Stanford and INSEAD business schools.